open access: Resistance to PARP-Inhibitors in Cancer Therapy | Frontiers in Pharmacology of Anti-Cancer Drugs Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Saturday, March 02, 2013

open access: Resistance to PARP-Inhibitors in Cancer Therapy | Frontiers in Pharmacology of Anti-Cancer Drugs




Article
 
"   There are 18 members of the PARP family of proteins, but therapeutic effect of PARPi on cancer cells is observed only in conjunction with DNA damage; hence DNA damage-responsive PARPs are the most
 likely mediators of PARPi effect......" 

Conclusion

In cancer treatment with PARPi, the personalization of therapy is important because many factors can influence the efficiency of PARPi, such as HR and NHEJ status, PARP-1 levels or its activity and finally other factors that influence intracellular concentrations of PARPi. Therefore, it would be necessary to assess the status of these controlling factors before beginning the treatment with PARPi (Lord and Ashworth, 2012; Ratner et al., 2012). A thorough understanding of different mechanisms for the resistance to PARPi will permit us to design better PARPi monotherapy as well as combination therapy, and will allow us to identify conditions that can re-sensitize tumor cells to PARPi; and thus treat cancer patients more efficiently.
 


There are 18 members of the PARP family of proteins, but therapeutic effect of PARPi on cancer cells is observed only in conjunction with DNA damage; hence DNA damage-responsive PARPs are the most likely mediators of PARPi effect. - See more at: http://www.frontiersin.org/Pharmacology_of_Anti-Cancer_Drugs/10.3389/fphar.2013.00018/full#sthash.wXwDkNj1.dpuf
There are 18 members of the PARP family of proteins, but therapeutic effect of PARPi on cancer cells is observed only in conjunction with DNA damage; hence DNA damage-responsive PARPs are the most likely mediators of PARPi effect. - See more at: http://www.frontiersin.org/Pharmacology_of_Anti-Cancer_Drugs/10.3389/fphar.2013.00018/full#sthash.wXwDkNj1.dpuf
There are 18 members of the PARP family of proteins, but therapeutic effect of PARPi on cancer cells is observed only in conjunction with DNA damage; hence DNA damage-responsive PARPs are the most likely mediators of PARPi effect. - See more at: http://www.frontiersin.org/Pharmacology_of_Anti-Cancer_Drugs/10.3389/fphar.2013.00018/full#sthash.wXwDkNj1.dpuf
There are 18 members of the PARP family of proteins, but therapeutic effect of PARPi on cancer cells is observed only in conjunction with DNA damage; hence DNA damage-responsive PARPs are the most likely mediators of PARPi effect. - See more at: http://www.frontiersin.org/Pharmacology_of_Anti-Cancer_Drugs/10.3389/fphar.2013.00018/full#sthash.wXwDkNj1.dpuf
There are 18 members of the PARP family of proteins, but therapeutic effect of PARPi on cancer cells is observed only in conjunction with DNA damage; hence DNA damage-responsive PARPs are the most likely mediators of PARPi effect. - See more at: http://www.frontiersin.org/Pharmacology_of_Anti-Cancer_Drugs/10.3389/fphar.2013.00018/full#sthash.wXwDkNj1.dpuf
ere are 18 members of the PARP family of proteins, but therapeutic effect of PARPi on cancer cells is observed only in conjunction with DNA damage; hence DNA damage-responsive PARPs are the most likely mediators of PARPi effect. - See more at: http://www.frontiersin.org/Pharmacology_of_Anti-Cancer_Drugs/10.3389/fphar.2013.00018/full#sthash.wXwDkNj1.dpuf

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.